Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Kissei Pharmaceutical Co ( (JP:4547) ) is now available.
Kissei Pharmaceutical Co., Ltd. has entered into a licensing agreement with Viridian Therapeutics to acquire exclusive development and sales rights for veligrotug and VRDN-003 in Japan, both of which are potential treatments for thyroid eye disease (TED). This strategic move aligns with Kissei’s medium-term management plan ‘Beyond 80’, aimed at growth and expanding its research and development pipeline, particularly in the area of rare diseases. The agreement is expected to enhance Kissei’s market positioning in Japan and contribute to the treatment of TED, a condition with significant unmet medical needs.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a company operating in the pharmaceutical industry, focusing on the development and sales of medical treatments. The company is particularly involved in the research and development of treatments for rare and intractable diseases, aiming to expand its pipeline and contribute to patient care.
Average Trading Volume: 95,672
Technical Sentiment Signal: Buy
Current Market Cap: Yen174.6B
For detailed information about 4547 stock, go to TipRanks’ Stock Analysis page.